NCT03412877 2026-03-17
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
17 trialsNCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01174121 2026-03-04
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02830724 2026-01-16
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00001426 2018-04-05
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00072566 2015-05-12
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002477 2013-12-18
Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00025441 2013-12-04
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004921 2013-09-17
High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002474 2013-05-30
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed